Introduction
Patients with chronic kidney disease (CKD), and in particular endstage renal disease (ESRD), have a dramatically increased risk for cardiovascular events. 1, 2 However, whether cardiovascular event rates differ according to the underlying cause of kidney failure has not adequately been explored. Patients with glomerular diseases in particular might have unique risk factors for cardiovascular disease development, including systemic inflammation [e.g. in vasculitis or lupus nephritis (LN)], medication-related toxicity lar disease-specific effect or is instead attributable to more general features common to all causes of kidney disease (e.g. impaired kidney function, proteinuria, metabolic derangements) has not been examined. The United States Renal Data System (USRDS)-a national registry of virtually all patients who commence dialysis or receive a kidney transplant in the USA-offers an opportunity to study this important question. By 'levelling the playing field' with respect to severity of kidney dysfunction, examining cardiovascular outcomes in a population of patients who uniformly have advanced ESRD might help to disentangle the influence of cause of kidney disease from that of more general kidney dysfunction. Identifying differences in cardiovascular event rates across patients with different underlying causes of ESRD might inform understanding of disease mechanisms as well as identify highrisk patient groups to be targeted for cardiovascular care and for enrolment in future clinical trials.
We thus examined cardiovascular and cerebrovascular event rates after dialysis initiation among patients with ESRD attributed to any of eight causes of ESRD [six subtypes of glomerular disease, diabetic nephropathy (DN), or autosomal dominant polycystic kidney disease (ADPKD)] who initiated haemodialysis or peritoneal dialysis in the USA between 1997 and 2014. We aimed to identify independent associations between cause of ESRD and cardiovascular event frequencies after dialysis initiation, using national ESRD registry data.
Methods

Data sources
The USRDS, incorporating Medicare Institutional (Part A) and Physician/ Supplier (Part B) insurance claims data, was our primary data source. The USRDS contains records for virtually all patients who receive a kidney transplant or who are maintained on dialysis in the USA. We obtained cause of ESRD, demographic characteristics, comorbidities, laboratory values, and body mass index (BMI) from patient and medevid files: these data are derived from Centers for Medicare & Medicaid Services (CMS) Medical Evidence Reports (Form CMS-2728) submitted by nephrologists within 45 days of a patient commencing a new ESRD treatment. We obtained initial ESRD treatment modality from the rxhist60 file. We used US Census Bureau data to obtain socioeconomic factors at the residential ZIP code level, as a proxy for patient-level socioeconomic status. We used year 2000 Decennial Census data, or American Community Survey (ACS) 5-year data (2007) (2008) (2009) (2010) (2011) , respectively, for patients starting dialysis prior to or after 2006. 7, 8 We obtained outcome data for non-fatal cardiovascular events from Medicare Institutional (Part A) and Physician/ Supplier (Part B) files. We obtained outcomes data for cardiovascular and non-cardiovascular deaths from the patient file: these data are derived from the Death Notification (form CMS-2746) submitted by nephrologists when a patient receiving ESRD treatment dies. M.M.O., S.L., and M.E.M. had full access to all the data in the study, and each take responsibility for its integrity and the data analysis.
Patient population
We identified all adult patients (> _18 years) who commenced haemodialysis or peritoneal dialysis in the USA between 1 January 1997 and 1 October 2014 and whose ESRD was reported to be due to any of eight more common and distinct causes of kidney disease i.e. one of the six glomerular disease subtypes [focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN), membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN), LN, or vasculitis], DN, or ADPKD. We excluded patients who were missing information on sex or on first ESRD treatment modality (i.e. not known to have started haemodialysis or peritoneal dialysis as a first ESRD treatment modality), who were aged >100 years, who resided outside of the continental US (i.e. Alaska, Hawaii, or the American Territories) or who had a pre-emptive kidney transplant prior to receiving any maintenance dialysis. We also excluded patients who died, discontinued dialysis, received a kidney transplant, or did not yet have Medicare Parts A&B as their primary insurance within the first 90 days after dialysis initiation.
Exposure
Cause of kidney disease was the primary exposure. We chose IgAN as our reference group, based on our prior report that mortality after dialysis initiation is lowest in this patient group. 9 Cause of ESRD was defined as that reported by treating nephrologists in patients' initial Medical Evidence Report. The cause does not need to be confirmed by kidney biopsy and only one 'primary' cause of kidney disease, as determined by the treating nephrologist, is collected per patient (per instructions: 'if there are several probable causes, please choose one as primary'). A prior validation study determined that selection of a glomerular disease subtype on the Medical Evidence Report had a high positive predictive value (>90%), but low sensitivity (< _30%), for detecting true biopsy-confirmed glomerular disease diagnoses.
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Outcomes
Our main cardiovascular outcome was a composite of first myocardial infarction (MI), first ischaemic stroke, or cardiovascular death, with followup time starting on Day 91 after dialysis initiation. We defined MI as an ICD-9 code of 410.xx as a primary, or 410.x1 as a non-primary, hospitalization diagnosis code, or acute MI as a designated cause of death on a Death Notification (cause of death codes 02 or 23). We defined stroke as an ICD-9 code for ischaemic stroke (433.x1, 434.x1) as a primary hospitalization diagnosis code, or stroke as a designated cause of death on a Death Notification (cause of death code 36). We defined cardiovascular death as any cardiovascular or cerebrovascular cause of death on a Death Notification, including cause of death codes 02 (myocardial infarction, acute), 23 (myocardial infarction, acute), 25 (pericarditis, including cardiac tamponade), 26 (atherosclerotic heart disease), 27 (cardiomyopathy), 28 (cardiac arrhythmia), 29 (cardiac arrest, cause unknown), 30 (valvular heart disease), 31 (pulmonary oedema due to exogenous fluid), 32 (congestive heart failure), or 36 (cerebro-vascular accident including intracranial haemorrhage). We also examined individual components of the composite outcome. Kidney transplantation and non-cardiovascular deaths were treated as competing events in our primary analyses, and as censoring events in a sensitivity analysis. We chose to model death and transplantation as competing rather than censoring events since death precludes the observation of a cardiovascular event and transplantation might alter its probability of occurrence. 
Statistical analyses
We examined unadjusted differences in baseline characteristics across cause of ESRD groups using cross tabulation and distribution plots. We summarized categorical variables as frequencies and percentages and continuous variables as means and standard deviations (SDs), or as medians and interquartile ranges (IQRs), as appropriate. We computed unadjusted rates of the composite and individual cardiovascular outcomes for each cause of ESRD, based on the number of events observed per person-year starting at Day 91 after dialysis initiation. We used stacked cumulative incidence plots to illustrate the cumulative incidences of individual components of the composite outcome along with the competing events of kidney transplantation and death, using the cumulative incidence function modelled by flexible parametric models. 14, 15 By this method, first occurring events are plotted, including:
transplantation, non-CV death, CV death, non-fatal MI, and non-fatal stroke. For events occurring on the same day ('ties') we used the following prioritization algorithm: kidney transplantation, non-CV death, CV death, non-fatal MI, and non-fatal stroke. In order to account for the competing risks of kidney transplantation and death due to non-cardiovascular causes, we used the proportional sub-distribution hazard model (Fine and Gray) to compute subdistribution hazard ratios (HRs) and 95% confidence intervals (CIs) comparing causes of ESRD for each outcome separately, with IgAN as the reference group. 16 Models were stratified by year of dialysis initiation. The sub-distribution hazard is defined as the probability of the outcome event occurring at time t, given that the patient has not yet experienced an outcome event, but may have experienced a competing event (transplantation or death). Thus, the sub-distribution HR can be used to directly answer the question of whether patients with comparator causes of ESRD are more likely to experience a cardiovascular event when compared to those with IgAN, in patients who are either event-free or who have experienced the competing event (death or transplantation). 17 As a sensitivity analysis, we censored patients at death or kidney transplantation and used Cox proportional hazards regression to obtain causespecific HRs. Here, individuals with competing events are removed from the risk set at the time of the competing event and the hazard rate is being evaluated in subjects who are still alive and have not undergone transplantation.
For all analyses, we added covariates to regression models sequentially to account for confounding. Model 1 included cause of ESRD. Model 2 added demographics. Model 3 added socioeconomic characteristics. Model 4 added clinical characteristics i.e. comorbidities (including a prior history of coronary heart disease or cerebrovascular disease), dialysis modality, and BMI. Finally, model 5 added baseline laboratory values.
We used log(-log) plots of 1-cumulative incidence function and plots of Loess smoothed scaled Schoenfeld residuals to examine the proportional hazards assumption. 17, 18 Besides visual interpretation of these plots, we also performed a global test combining zero-slope tests on the scaled Schoenfeld residuals plotted against time for each covariate in the model. 19 
Missing data
The frequency of missing covariate data ranged from <1% (e.g. Hispanic ethnicity) to 25% (serum albumin), and 32% of patients had at least one missing variable. Missing data were similarly distributed across all categories of the exposure variable. We assumed these data to be missing at random and used multiple imputation (using SAS proc mi) through the joint modelling approach to generate 30 imputed data sets. 20 Besides the event indicator and the Nelson-Aalen estimate of the cumulative hazard, the imputation model also included all variables in the fully adjusted model. As a sensitivity analysis, we also conducted a complete-case analysis, where subjects with any missing data were excluded. Statistical analyses were performed using a combination of SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) and Stata version 13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA).
A Stanford University School of Medicine Institutional Review Board approved the study (IRB protocol number 17904). De-identified data were used throughout and patient consent was not required.
Results
Patient characteristics
We identified 658 168 adult patients with ESRD attributed to one of six glomerular disease subtypes (IgAN n = 9828, FSGS n = 27 029, MN n = 5660, MPGN n = 3718, LN n = 12 398, vasculitis n = 5023), DN (n = 567 778) or ADPKD (n = 26 734), who initiated haemodialysis or peritoneal dialysis in the continental US between 1 January 1997 and 1 October 2014, Figure 1 . Baseline characteristics of the study cohort are summarized in Table 1 (online only). Demographic characteristics differed considerably by cause of ESRD: average age ranged from 40.8 (SD 15.0) years in LN to 62.7 (SD 15.8) years in vasculitis; male sex ranged from 18.4% in LN to 66.7% in IgAN; black race ranged from 7.9% in IgAN to 52.3% in LN; and Hispanic ethnicity ranged from 7.8% in FSGS to 15.9% in DN. Use of peritoneal dialysis as a first ESRD treatment modality was highest in IgAN (24.4%) and lowest in DN (8.5%). Patients with IgAN, LN, and ADPKD had comparatively low comorbidity frequencies, whereas patients with DN had the highest comorbidity burden. Pre-existing atherosclerotic heart disease was reported in 6.0% of patients with LN, 7. As observed for the composite outcome, event rates for all individual outcomes were lowest for patients with IgAN and highest for patients with DN, Table 2 . We next considered unadjusted event rates in a model that accounted only for first events, thus projecting a patient's expected clinical course following dialysis initiation according to their cause of ESRD. Take home figure and Supplementary material online, Table S1 show the cumulative incidences of cardiovascular outcomes and competing events (non-cardiovascular deaths or kidney transplantation) in the 5 years following dialysis initiation (starting at Day 91). By 5 years and 90 days after dialysis initiation, 49.3% of patients with IgAN had received a kidney transplant, and of the remaining patients 10.3% had experienced a fatal or non-fatal cardiovascular event, and 10.0% had died from a non-cardiovascular cause. In contrast, only 8.1% of patients with DN had received a kidney transplant, and of the remaining patients 40.1% had experienced a fatal or non-fatal cardiovascular event and 25.2% a non-cardiovascular death. The 5-year cumulative incidences of any cardiovascular event (prior to kidney transplantation) were 16.3% in ADPKD and ranged from between 16.6% in LN and 23% in MN among the comparator glomerular disease subtypes i.e. higher than in IgAN (10.3%) and lower than in DN (40.1%) in all cases.
Cardiovascular outcomes: adjusted
Unadjusted and adjusted HRs for the composite event and each of the individual cardiovascular outcomes are shown in Table 3 . Sequential adjustment for factors that might confound or explain associations between cause of ESRD and cardiovascular event rates generally attenuated the HR relative to IgAN (with the singular exception of LN, for which HRs increased after demographic adjustment but then decreased after further adjustment). Even in fully adjusted models, however, significant heterogeneity in HRs for cardiovascular outcomes according to cause of ESRD were observed, Table 3 and Figure 2 . When compared to IgAN, patients with any other cause of ESRD were significantly more likely to experience the composite and each of the individual cardiovascular outcomes. For the composite outcome, the fully adjusted HR was highest for DN (aHR = 2.97, 95% CI 2.77-3.20), next highest for LN (aHR = 1.86, 95% CI 1.71-2.03), intermediary between 1.55 and 1.67 in the other four comparator glomerular diseases (FSGS, MN, MPGN, and vasculitis), and lowest in ADPKD at 1.29 (95% CI 1.19-1.39). Considering individual components of the composite, the relative hazards for MI, stroke, or cardiovascular mortality were also highest in DN (aHRs of 3.01, 3.47, and 2.44, respectively), but also significantly higher for all other subtypes of glomerular disease or for ADPKD when compared to IgAN, Table 3 and Figure 2 .
Sensitivity analyses computing cause-specific HRs (whereby transplantation and non-cardiovascular deaths were handled as censoring rather than competing events) or including only patients without any missing data (i.e. a complete-case analysis) did not materially alter findings, Supplementary material online, Tables S2 and S3.
Discussion
In this population-based study of 658 168 adult patients who initiated dialysis in the USA over the last 20 years, we identified significant associations between underlying cause of ESRD and cardiovascular and cerebrovascular event rates after dialysis initiation. The associations persisted even after careful adjustment for between-group differences in demographic, socioeconomic, and comorbidity characteristics (e.g. younger age, female sex, and black race were considerably more frequent in patients with LN). Of particular interest, we determined significant heterogeneity across six individual .. .......................................................................................... glomerular disease subtypes, challenging the prevailing research paradigm to group these disease subtypes together when examining ESRD outcomes. We previously demonstrated that the adjusted hazard for all-cause mortality following dialysis initiation or kidney transplantation was lower in IgAN than in other glomerular disease subtypes, with the hazard being highest in patients with LN. 9, 12 In this study, we begin to close the knowledge gaps created by our prior findings, by determining that differences in all-cause mortality might largely be explained by differences in cardiovascular morbidity and mortality across causes of ESRD. In doing so, we create new opportunities for scientific exploration, drug discovery, clinical trial design, and patient management approaches. Prior studies examining cardiovascular outcomes in patients with glomerular disease with or without ESRD primarily focused on a single glomerular disease subtype rather than comparing across subtypes. In a population-level Danish study that compared cardiovascular outcomes in patients with LN to those in the general population, an almost seven-fold higher risk for ischaemic heart disease overall, with a 19-fold higher risk among those undergoing renal replacement therapy, was observed. 4 However, comparisons to patients with other causes of kidney disease were not performed.
Another study compared cardiovascular outcomes in US patients with ESRD due to LN to those in patients with any other cause of ESRD and failed to identify an increased risk in those with LN. 21 However, heterogeneity within the comparator group (e.g. distinguishing outcomes in those with ESRD due to IgAN from those with ESRD due to DN) was not explored, and thus disease-specific signals were likely missed. With respect to glomerular disease subtypes other than LN, high rates of vascular events have been reported in non-ESRD populations with vasculitis, 3 MN, 5 IgA nephropathy, 6 and the ApoL1 risk alleles associated with FSGS. 22 At the same time, both CKD 1 and the nephrotic syndrome 23, 24 have more generally been identified as strong cardiovascular risk factors. For example, age-and sex-standardized mortality rates in European dialysis patients compared with the general population were reported to be 11.0 (95% CI 10.6-11.4) for myocardial infarction, 8.4 (95% CI 8.0-8.8) for stroke, and 8.3 (95% CI 8.0-8.5) for other cardiovascular diseases. 25 In this same study, HR's for cardiovascular death by cause of ESRD (with ADPKD as the reference group) were also reported, albeit not as the primary focus of the manuscript, with findings consistent with those herein reported i.e. HR's in diabetic nephropathy of 4.1 (3.4-4.9) for MI and 3.5 (2.8-4.4) for stroke, and HRs in glomerulonephritis of 1.3 (1.1-1.7) for MI and 1.6 (1.3-2.1) for stroke. However, non-fatal events were not reported, analyses were only adjusted for four variables (age, sex, cause of kidney disease, and dialysis modality), baseline characteristics were not specifically compared across causes of ESRD, and all subtypes of glomerulonephritis were included together in a single disease group. Thus, our study expands upon these prior findings and translates them to a US patient population.
There are a number of plausible hypotheses for our observed findings. The persistence of a particularly increased hazard for cardiovascular events even after adjustment for a prior history of diabetes among patients with diabetic nephropathy as a cause of ESRD likely speaks to the fact that development of severe nephropathy resulting in ESRD is a marker of prior poor diabetic control. We also suggest some hypotheses for why patients with IgAN or ADPKD had lower rates of cardiovascular events than those with other primary (FSGS, MN, MPGN) or secondary (LN, vasculitis) glomerular diseases. First, patients with IgAN or ADPKD do not typically develop the nephrotic syndrome (heavy proteinuria, hypoalbuminaemia, and oedema), which itself results in hyperlipidaemia, increased thrombotic risk, and (through these mechanisms and others) heightened cardiovascular risk. 23 Our study has some limitations. First, we included only patients who had survived long enough to develop ESRD. Whether similar differences exist in cardiovascular event rates across underlying causes of kidney disease in patients with earlier stages of kidney dysfunction could not be evaluated using this data source. Such an analysis is challenging to perform at any large-scale level in the USA, given the absence of a national pre-ESRD glomerular disease registry, the rarity of glomerular disease subtypes at individual centres, and the nonspecific nature of diagnosis codes for glomerular disease in administrative healthcare records. However, with the recent establishment of two large, NIH-funded, prospective glomerular disease cohort studies [Cure Glomerulonephropathy (CureGN) 28 and the Nephrotic Syndrome Study Network (NEPTUNE 29 )], these barriers may soon be overcome. Second, without access to detailed clinical records or prescription data for most patients prior to dialysis initiation, we could not adjust for severity of pre-existing atherosclerotic disease (most patients lacked Medicare insurance prior to dialysis initiation and thus comorbidities were taken from physician-reported diagnoses on Medical Evidence Reports rather than from Medicare insurance claims), nor for other relevant factors such as baseline lipid values (only collected on Medical Evidence Reports since 2005 and missing in more than two-thirds of patients even since then) or baseline medications (e.g. statins or medications blocking the reninangiotensin-aldosterone system). Further, we could not explore the underlying pathogenic mechanisms contributing to differential risks across cause of ESRD groups, including the extent to which these differences are disease-related (e.g. history of thrombophilia or dyslipidaemia in patients with nephrotic syndrome or of systemic inflammation in patients with LN or vasculitis), treatment-related (e.g. corticosteroid-associated diabetes or calcineurin inhibitor-induced hypertension), or indeed related to the dialysis procedure itself (e.g. propensity for intra-dialytic hypotension or higher inter-dialytic weight gains). Laboratory data were missing in many patients and comorbidities were likely under-reported (e.g. only 89% of patients with diabetic nephropathy were reported to have diabetes mellitus), 30 factors that might have introduced bias or resulted in incomplete adjustment for confounding. Finally, although we studied prospectively collected data (i.e. Medical Evidence Reports, Medicare insurance claims, and Death Notifications collected 'real time' shortly after events occur), these data were collected as part of routine clinical care and not with the specific objectives of this study in mind: thus, incomplete capture or misclassification of outcome events is possible. Nevertheless, our study has several strengths. We examined a large, population-based, patient cohort, and thus our study findings are broadly generalizable to most US patients with ESRD due to glomerular disease, DN, or ADPKD. We were sufficiently powered to adjust for multiple potential confounders of observed associations between cause of ESRD and cardiovascular and cerebrovascular events (e.g. patients with DN were older and predominantly male, whereas those with LN were younger and predominantly female, resulting in attenuation and exaggeration of effect estimates, respectively, after demographic adjustment), thus enabling us to identify independent, disease-specific associations. We used advanced statistical techniques to optimize the internal validity of our findings, including use of multiple imputation to handle missing data, and comparison of sub-distribution and cause-specific Cox regression modelling approaches in an effort to better understand exposure-outcome associations. In summary, we affirm high cardiovascular event rates in US patients with ESRD treated with dialysis, confirming their appropriate classification as 'very high risk' in cardiovascular disease prevention clinical guidelines. 31 Importantly, we have shown that relative hazards for cardiovascular events differ considerably by cause of ESRD. Although we cannot determine the exact underlying reasons for these differences, our data strongly support the presence of independent disease-specific influences. We advocate for the conduct of clinical studies that examine the impact of novel disease-specific interventions (e.g. control of systemic inflammation, prescription of less toxic immunosuppressive medications, more intensive control of nephrosis-associated hyperlipidaemia) on cardiovascular risk, as well as experiments that generate new knowledge regarding underlying disease biology. In the interim, we urge clinicians to actively consider and apply best practice cardiovascular guidelines 31 when treating dialysis patients, with the goal of eradicating disparities and improving outcomes.
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